AI assistant
Novacyt Director's Dealing 2022
1557_dirs_2022-07-15_3e8c947e-5ad9-43c5-a2b3-899e6be2543c.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 5744S
Novacyt S.A.
15 July 2022
Novacyt S.A.
("Novacyt" or the "Company")
Director/PDMR Shareholding
Paris, France and Camberley, UK - 15 July 2022 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 14 July 2022, Dr Edwin Snape, a Non-executive Director of the Company, transferred 17,919 ordinary shares of €1/15 each in the Company for nil consideration from CIC Market Solutions - Emetteur to JPMorgan Chase Bank, N.A.
Dr. Snape's beneficial shareholding is unchanged at 17,919 ordinary shares representing 0.03% of the Company's issued share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1.
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Dr Edwin Snape, Non-executive Director
2.
Reason for the Notification
a)
Position/status
Non-executive Director
b)
Initial notification/ Amendment
Initial
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Novacyt S.A.
b)
LEI
213800BWAC2BF295EG28
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the Financial instrument, type of instrument
ordinary shares of €1/15 each
Identification code
FR0010397232
b)
Nature of the transaction
Transfer of shares from one nominee account to another nominee account for nil consideration with no change in beneficial ownership
c)
Price(s) and volume(s)
| Price | Volume |
| nil | 17,919 |
d)
Aggregated information:
· Aggregated volume
· Price
N/A
e)
Date of the transaction
11 July 2022
f)
Place of the transaction
Euronext Growth
Contacts
Novacyt SA
David Allmond, Chief Executive Officer
James McCarthy, Chief Financial Officer
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
Numis Securities Limited (Joint Broker)
Freddie Barnfield / James Black / Duncan Monteith
+44 (0)20 7260 1000
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick Petit
+33 (1) 42 22 10 10
[email protected]; [email protected]
FTI Consulting (International)
Victoria Foster Mitchell / Alex Shaw
+44 (0)20 3727 1000
[email protected] / [email protected]
FTI Consulting (France)
Arnaud de Cheffontaines
+33 (0)147 03 69 48
About Novacyt Group
The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company supplies an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.
For more information, please refer to the website: www.novacyt.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHGPUCWMUPPPPC